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Nifurtimox Is Effective Against 
Neural Tumor Cells and Is 
Synergistic with Buthionine 
Sulfoximine
Michael Du, Linna Zhang, Kathleen A. Scorsone, Sarah E. Woodfield & Peter E. Zage
Children with aggressive neural tumors have poor survival rates and novel therapies are needed. 
Previous studies have identified nifurtimox and buthionine sulfoximine (BSO) as effective agents 
in children with neuroblastoma and medulloblastoma. We hypothesized that nifurtimox would be 
effective against other neural tumor cells and would be synergistic with BSO. We determined neural 
tumor cell viability before and after treatment with nifurtimox using MTT assays. Assays for DNA 
ladder formation and poly-ADP ribose polymerase (PARP) cleavage were performed to measure the 
induction of apoptosis after nifurtimox treatment. Inhibition of intracellular signaling was measured by 
Western blot analysis of treated and untreated cells. Tumor cells were then treated with combinations 
of nifurtimox and BSO and evaluated for viability using MTT assays. All neural tumor cell lines were 
sensitive to nifurtimox, and IC50 values ranged from approximately 20 to 210 μM. Nifurtimox treatment 
inhibited ERK phosphorylation and induced apoptosis in tumor cells. Furthermore, the combination 
of nifurtimox and BSO demonstrated significant synergistic efficacy in all tested cell lines. Additional 
preclinical and clinical studies of the combination of nifurtimox and BSO in patients with neural tumors 
are warranted.
Neural tumors, including tumors of both the central and peripheral nervous systems, are common in both adults 
and children and are often associated with aggressive disease and poor prognosis. Survivors of these neural 
tumors suffer from significant late effects from therapy. Neuroblastoma and medulloblastoma are among the most 
common forms of cancer seen in children, while glioblastoma is the most common and most aggressive malig-
nant primary brain tumor that affects both adults and children. Patients with aggressive forms of these neural 
tumors have very poor outcomes, with limited responses to treatment and frequent relapses. While recently intro-
duced reatment strategies, such as immunotherapy for upfront treatment of neuroblastoma and new molecular 
prognostication for medulloblastoma, have resulted in some improvement in patient outcomes, novel therapies 
continue to be sorely needed for the patients with these neural tumors.
Nifurtimox is a nitrofuran compound that has been used since the 1970’s as a primary form of therapy for 
Chagas’ disease, a parasitic infection caused by Trypanosoma cruzi1,2. Nifurtimox has been shown to act through 
production of reduced oxygen metabolites superoxide and hydrogen peroxide, for which the parasites have lower 
detoxification capacity1,3. Preclinical studies have also shown that nifurtimox treatment generates reactive oxygen 
species and inhibits neuroblastoma and medulloblastoma cell growth in vitro and in vivo4,5, and in early phase 
clinical trials, nifurtimox was well tolerated by children with relapsed neuroblastoma, with mild nausea, vomiting 
and anorexia being the most commonly observed side effects. Tumor responses were seen in patients treated with 
nifurtimox at a dose of 30 mg/kg/day both as a single agent and in combination with chemotherapy6.
Buthionine sulfoximine (BSO) is a selective inhibitor of γ -glutamylcysteine synthetase (γ -GCS), the rate lim-
iting enzyme in glutathione (GSH) synthesis7. BSO has been shown to increase the efficacy of nifurtimox against 
T. cruzi8,9 and has also been shown to be an effective modulator of GSH-mediated chemoresistance by increasing 
the in vitro cytotoxicity of alkylating agents and radiation10–14. BSO has been tested in animal studies and in 
human phase I trials for adults with solid tumors, with documented clinical responses in patients with melanoma, 
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ovarian carcinoma and small cell carcinoma of the lung treated with the combination of BSO and melphalan15,16. 
BSO was also shown to be effective against neuroblastoma tumor cells, both alone and in combination with 
melphalan17–19, and prior studies have reported that treatment of mice with human glioma and medulloblastoma 
xenograft tumors with BSO prior to melphalan resulted in increased survival20. Furthermore, a pilot clinical trial 
for treatment of children with recurrent neuroblastoma with BSO combined with melphalan demonstrated an 
18% response rate21, suggesting a potential role for BSO in combination with other therapies for cancer patients.
Despite these prior studies, the efficacy of nifurtimox against other neural tumor cells has not been well char-
acterized, and the efficacy of the combination of nifurtimox and BSO has not been fully explored in preclinical 
models of cancer. Based on the evidence for the potential efficacy of nifurtimox and BSO as single agents against 
neural tumors and the efficacy of the combination against T. cruzi, we hypothesized that nifurtimox would be 
effective against neural tumor cells alone and in combination with BSO.
Materials and Methods
Cells and culture conditions. The neuroblastoma cell lines used in this study have been previously uti-
lized by our laboratory22,23, and were either purchased from American Type Culture Collection (ATCC, www.
atcc.org) or were generously provided by Susan Cohn (The University of Chicago Children’s Hospital, Chicago, 
IL, USA), John Maris (Children’s Hospital of Philadelphia, Philadelphia, PA, USA), or the Children’s Oncology 
Group (COG) Cell Culture and Xenograft Repository (www.cogcell.org). Neural tumor cell lines U-87, U373, 
CHLA-02-ATRT and PFSK-1 were purchased from ATCC. Medulloblastoma cell lines Daoy and D283 were gen-
erously provided by Vidya Gopalakrishnan (The University of Texas MD Anderson Cancer Center, Houston, TX, 
USA). TC-71, 143B, MG-63, MMH-ES, RD-ES, SK-ES-1 and SK-N-MC cells were generously provided by Jason 
Yustein (Baylor College of Medicine, Houston, TX, USA). Cell lines were grown at 37 °C in 5% CO2 in appropri-
ate media (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Life 
Technologies, Grand Island, NY), L-glutamine, sodium pyruvate and non-essential amino acids (Sigma-Aldrich, 
St. Louis, MO). All cell lines were authenticated by DNA profiling prior to use.
Therapeutic agents. Nifurtimox was generously provided by MetronomX, Inc. (Houston, TX). A 70 mM 
stock solution was generated in DMSO (Sigma) and stored at − 20 °C. Nifurtimox was diluted in PBS to appropri-
ate concentrations immediately before use. BSO (Sigma) was diluted in water (50 mg/mL) and stored at − 20 °C. 
BSO was warmed and diluted in PBS to appropriate concentrations immediately prior to use.
Cell viability assays. The viability of cells exposed to nifurtimox and BSO was determined using a modi-
fied methyl tetrazolium (MTT; Sigma) assay as previously described22,23. 0.5–1.0 × 104 cells/well of exponentially 
growing cells were plated in 96-well plates. 24 hours later, nifurtimox or BSO was added to each well at specified 
concentrations. After 72, 96, or 120 hours of continuous drug exposure, 15 μ L of 5 mg/ml MTT was added to each 
well and the plates were incubated for 4 hours at 37 °C. Medium was replaced with 150 μ L of DMSO and the opti-
cal density (OD) was measured at 550 nm using a microplate spectrophotometer (Anthos Analytical, Durham, 
NC). Cell numbers were estimated from OD measurements in individual wells. Relative cell viability was calcu-
lated by subtracting the background OD of media alone and then dividing by the OD of control wells. Replicates 
of three wells were used for each drug concentration and assays were duplicated on separate days. IC50 values 
were derived using best-fit trendlines and values calculated using the relevant curve-fit equations.
For combination studies using nifurtimox and BSO, average cell viability for each drug alone was calculated 
and plotted against individual drug concentrations. Cells were then plated as above, treated with the specified 
concentrations of nifurtimox and BSO (with separate 96-well plates for each combination) for 72 hours, with 
cell viability determined as above and combination indices calculated using CalcuSyn v2.11 software (Biosoft, 
Cambridge, UK).
Inhibition of Signaling Assays. Neural tumor cell lines were plated at approximately 80% confluency in 
60 mm plates and allowed to adhere overnight. Plates were washed twice with PBS and incubated in media for 
three hours, followed by the addition of nifurtimox for 72 hours. Cells were washed with PBS and lysed with 
M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL) with protease inhibitor 
(Sigma) at the completion of each experiment. Lysates were centrifuged and supernatants were collected.
Protein concentration in each sample was measured using a protein assay dye reagent (Bio-Rad, Hercules, CA). 
30–50 μ g total denatured protein from each cell line was separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA) using stand-
ard techniques. Membranes were blocked in Odyssey blocking buffer (Li-Cor, Lincoln, NE) for 1 hour at room 
temperature and then incubated with primary antibodies to total ERK (#4695, 1:1000; Cell Signaling, Danvers, 
MA, USA), phosphorylated ERK (#4370, 1:1000; Cell Signaling), total MEK (#9126, 1:1000; Cell Signaling), 
phosphorylated MEK (#9154, 1:1000; Cell Signaling), β -actin (#A3853, 1:5000; Sigma), or vinculin (ab1290002, 
1:2000; Abcam). All antibodies were diluted in Odyssey blocking buffer (Li-Cor) with 0.1% Tween-20. 
Bound primary antibodies were incubated for 1 hour at room temperature with IRDye800 conjugated affinity 
purified anti-rabbit or anti-mouse secondary antibody (1:2000; Rockland, Gilbertsville, PA) and the signal was 
visualized on an Odyssey infrared imaging system (Li-Cor).
Apoptosis assays. Apoptosis was measured using assays for DNA ladder formation and poly-ADP ribose 
polymerase (PARP) cleavage. For DNA ladder formation assays, neural tumor cells were plated in 6-well plates 
and allowed to adhere overnight. Cells were then washed twice with PBS, followed by the addition of nifurtimox 
for 24 hours. Cells were collected and incubated in cell lysis buffer (100 mM Tris pH 8.0, 50 mM EDTA and 1% 
SDS (w/v)) for 10 minutes at room temperature. The mixture was vortexed with protein precipitation buffer (6 M 
NaCl) at room temperature followed by centrifugation. Genomic DNA was precipitated from the supernatant 
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with isopropyl alcohol. After centrifugation, the remaining DNA precipitate was washed with 70% ethanol. The 
final DNA was dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA) at 37 °C. A Nanodrop spectrophotometer 
(Thermo Scientific) was used to measure DNA concentrations. 5 μ g of total genomic DNA was separated on a 1% 
agarose gel and photographed with a VersaDoc molecular imager (Bio-Rad).
For PARP cleavage assays, neural tumor cells were plated as above and exposed to nifurtimox for 72 hours. 
Treated and untreated control cells were washed and lysed as above and 30–50 μ g total denatured protein from 
each cell line was separated by SDS-PAGE and transferred to nitrocellulose membranes as above. Membranes 
were blocked and incubated with primary antibodies to PARP1 (#9542, 1:500, Cell Signaling). After exposure to 
secondary antibodies as above, images were obtained using the Odyssey infared imaging system.
Results
Neural tumor cell line sensitivity to nifurtimox. In order to determine the efficacy of nifurtimox 
against neural tumor cells, a panel of established human tumor cell lines were tested for sensitivity in vitro to 
a range of concentrations of nifurtimox using MTT assays. IC50 values were calculated and ranged from 20 to 
210 μ M (Fig. 1). Increased exposure time resulted in slightly decreased IC50 values (Supplemental Fig. 1). NGP 
and U373 tumor cells were among the most sensitive cell lines to nifurtimox, while SK-N-BE(2) and Daoy cells 
were among the least sensitive (Fig. 1). Most cell lines had IC50 values < 100 μ M, including 8 of 11 tested neuro-
blastoma and 5 of 6 tested CNS tumor cell lines, suggesting that neural tumor cells were particularly sensitive to 
nifurtimox.
Nifurtimox induces apoptosis and inhibits intracellular signaling in neural tumor cells. Based 
on the efficacy of nifurtimox as a single agent in our initial testing (Fig. 1) and the known ability of nifurtimox 
to penetrate the blood brain barrier24,25, we pursued further studies of nifurtimox in neural tumor cell lines. In 
order to determine the mechanism of decreased neural tumor cell viability after treatment with nifurtimox, we 
performed assays for DNA ladder formation and for cleavage of PARP to establish whether nifurtimox treatment 
induced apoptosis. DNA ladders and PARP cleavage were evident in tumor cells after treatment with nifurtimox 
(Fig. 2), suggesting that the decreased viability of tumor cells after nifurtimox treatment was secondary to induc-
tion of apoptosis.
Activity of the RAS/MAPK signaling pathway has been linked to the pathogenesis of multiple cancers in both 
adults and children26. To determine whether treatment with nifurtimox resulted in inhibition of these down-
stream signaling pathways, U373, U87 and PFSK-1 neural tumor cell lines were harvested before and after nifur-
timox treatment and Western blots for total and phosphorylated MEK and ERK were performed. Nifurtimox 
treatment resulted in loss of ERK phosphorylation in PFSK-1 cells and in increased phosphorylation of MEK 
Figure 1. Effects of nifurtimox on tumor cell lines. (A) panel of neuroblastoma (A), CNS (B) and sarcoma 
(C) tumor cell lines were treated with increasing concentrations of nifurtimox for 72 hours and cell viability was 
determined by MTT assays. (D) IC50 values were calculated for each cell line.
www.nature.com/scientificreports/
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and ERK in glioblastoma cell lines at low doses of nifurtimox, followed by significant reduction of MEK and ERK 
phosphorylation at doses above the determined IC50 values in these cell lines (Fig. 3).
Neural tumor cell line sensitivity to BSO and to the combination of nifurtimox and BSO. BSO 
has demonstrated antitumor activity in a number of preclinical cancer models of neural tumors17–20. In order to 
confirm the efficacy of BSO in neural tumor cell lines, 6 neuroblastoma, 2 glioblastoma, and 1 PNET cell line were 
treated with increasing concentrations of BSO, and viability was determined using MTT assays. BSO was effective 
against neural tumor cell lines, with IC50 values ranging from 36 to 1071 μ M (Fig. 4), consistent with previously 
reported IC50 values for BSO in other neuroblastoma cell lines18.
In order to determine whether BSO could enhance the efficacy of nifurtimox against neural tumor cells, 
the panel of neural tumor cell lines were treated with the combination of nifurtimox and BSO over a range of 
Figure 2. Nifurtimox treatment induces apoptosis in neural tumor cells. U373, U87 and PFSK-1 neural 
tumor cells were treated with nifurtimox at the concentrations shown and assayed by immunoblot for PARP 
cleavage (top) and by agarose gel electrophoresis for DNA ladder formation (bottom).
Figure 3. Nifurtimox treatment inhibits ERK phosphorylation in neural tumor cells. U373, U87 and 
PFSK-1 neural tumor cells were lysed at baseline (untreated) or after treatment with nifurtimox. Western blots 
were performed for total (ERK, MEK) and phosphorylated (pERK, pMEK) ERK and MEK. Vinculin was used 
as a protein loading control.
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concentrations. In each of the 9 tested cell lines, cell viability was dramatically reduced with the combination of 
nifurtimox and BSO, compared to either drug alone (Supplemental Fig. 2). Furthermore, calculated combination 
indices were consistently < 1 for most tested dosing combinations in each of the 9 cell lines (Fig. 5), suggesting 
synergistic efficacy of nifurtimox and BSO in neural tumor cell lines.
Discussion
New treatment strategies are clearly needed for patients with high-risk and recurrent neural tumors. We have 
demonstrated that the anti-trypanosomal agent nifurtimox is effective against neural tumor cells and is synergis-
tic with the GSH inhibitor BSO. Nifurtimox treatment results in reduced ERK phosphorylation and in induction 
of apoptosis and our results suggest that nifurtimox alone and in combination with BSO may be effective for 
patients with all types of neural tumors, including neuroblastoma, glioblastoma and medulloblastoma.
Figure 4. Effects of BSO on neural tumor cells. Neural tumor cells were treated with increasing 
concentrations of BSO for 72 hours and cell viability was determined by MTT assays (A). (B) IC50 values were 
calculated for each independent cell line.
Figure 5. Combination indices for nifurtimox plus BSO in neural tumor cell lines. Combination indices 
(CIs) were calculated for each cell line and isobolograms were generated using all calculated CIs for each 
individual cell line (left). CIs were then color coded and plotted for each individual cell line (right).
www.nature.com/scientificreports/
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Prior studies have demonstrated the efficacy of nifurtimox and BSO as single agents in selected neural tumor 
models4,5,17,18. Our results both confirm and expand these prior reports and demonstrate that nifurtimox is effec-
tive against a wide range of tumor cell types and that nifurtimox combined with BSO demonstrates synergistic 
drug efficacy. However, the specific disease subtypes and biologic prognostic features associated with responses to 
nifurtimox and BSO are currently unknown. We are currently investigating the associations with other biologic 
factors and signaling pathways with the responses of neural tumor cells to nifurtimox and BSO.
Oral nifurtimox has been used for long-term treatment of Chagas’ disease in adults at doses of 8 to 10 mg/kg/day 
and in children at 15 to 20 mg/kg/day27. When used to treat an acute T. cruzi infection, nifurtimox is administered 
for 90 days, but for chronic infection nifurtimox treatment continues for 120 days or longer27,28. Nifurtimox-related 
toxicities in adults primarily include nausea, vomiting, diarrhea, anorexia and weight loss along with irritability, 
sleep disorders and peripheral neuropathies28. During long-term treatment, additional secondary side-effects have 
included tremors, muscle weakness, mild paresthesia and polyneuritis29,30. Unlike adult patients, infants and young 
children with Chagas’ disease treated with nifurtimox only experience minor adverse events, including anorexia and 
diarrhea31,32. Toxicities observed in children with neuroblastoma treated with nifurtimox included anorexia, nausea, 
stomach pain, neuropathies, and seizures6, and pill compliance data showed that, on average, children treated with 
nifurtimox took 96.7% of their prescribed pills, showing that the treatment regimen could be easily followed. The 
maximum tolerated dose in this patient population was determined to be 30 mg/kg/day6.
We determined the efficacy of nifurtimox against a panel of neural tumor cell lines, with calculated IC50 
values between 20 and 210 μ M, similar to previously published results4,5. In healthy adults, serum levels of nifurti-
mox reached 2.6 μ M after a single 15 mg/kg oral dose33,34, while peak serum levels in children with neuroblastoma 
treated with single agent nifurtimox at 30 mg/kd/day exceeded 1 mM6, suggesting that serum levels required for 
tumor cell effects in our in vitro models are clinically achievable in patients with neural tumors.
A key limitation of many potential novel therapies for both adults and children with intracranial tumors is 
the inability of these agents to penetrate the blood brain barrier (BBB). Nifurtimox has been previously shown 
to penetrate the BBB in preclinical models24,25, and nifurtimox has demonstrated efficacy in late stage African 
trypanosomiasis (African sleeping sickness), defined by the presence of active CNS infection35,36. It is unclear 
whether the penetrability of the BBB is similar in patients with infection compared to those with malignancies. 
However, nifurtimox has demonstrated efficacy in intracranial orthotopic models of neural tumors4,5, suggesting 
that nifurtimox may be able to penetrate the BBB and reach levels with antitumor efficacy in patients with glio-
blastoma and other intracranial tumors.
The mechanism(s) underlying the efficacy of nifurtimox in neural tumors is not fully understood. Nifurtimox 
is a nitroheterocyclic compound that undergoes cellular reduction to nitro anion free radicals, hydrogen perox-
ide, and superoxide free radicals, which generate intracellular reactive oxygen species (ROS), leading to antitryp-
anosomal efficacy37. Nifurtimox has also been shown to induce apoptosis via induction of ROS in the presence of 
catecholamines in neuroblastoma preclinical models5. However, the mechanims of efficacy in tumor cells in the 
absence of catecholamines is not clear.
Glutathione (GSH) is a ubiquitous intracellular tri-peptide that acts as a key intracellular antioxidant to mini-
mize damage to important cellular components caused by ROS such as free radicals, peroxides, and heavy metals. 
The antitumor activity of many chemotherapy agents depends upon the induction of ROS, and inhibition of GSH 
has been shown to increase the efficacy of chemotherapy38. As a selective inhibitor of γ -GCS, the rate limiting 
enzyme in GSH synthesis, BSO has been shown to deplete GSH both in vitro and in vivo10,11,18, and BSO-mediated 
depletion of GSH renders cells susceptible to alkylating agent-mediated DNA damage, anthracycline-mediated 
lipid peroxidation of the cellular membranes, and ionizing radiation16–18. Indeed, BSO has been shown to be syn-
ergistic with multiple chemotherapy agents10,11,38–45.
BSO has been shown to be cytotoxic for neuroblastoma cell lines in vitro due to increased ROS18,19, and BSO 
has been shown to enhance the efficacy of nifurtimox in a murine model of Chagas’ Disease9, suggesting a likely 
mechanism for our observed synergistic efficacy with nifurtimox. Our determined IC50 values were similar to 
previously published values in similar cell lines18 and were also within the range of serum BSO levels seen in 
adults and children treated with BSO21,46, suggesting that serum levels of BSO in our in vitro models are clinically 
achievable in patients with neural tumors.
We have demonstrated that nifurtimox is effective against neural tumor cells and is synergistic with BSO. All 
tested neural and non-neural tumor cell lines were sensitive to nifurtimox, and in neural tumor cells, nifurti-
mox treatment inhibited ERK phosphorylation and induced apoptosis. The combination of nifurtimox and BSO 
demonstrated synergistic efficacy in tested cell lines, and further preclinical studies of the combination of nifur-
timox and BSO are warranted. Furthermore, the efficacy of this combination against neural tumor cells provides 
strong biological and clinical rationale for clinical testing of nifurtimox and BSO in patients with additional types 
of neural tumors.
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